ESC 2021: With ESC's new heart failure endorsement, AstraZeneca's blockbuster Farxiga is flying high
The European Society of Cardiology issued new guidelines for heart failure, recommending SGLT2s such as AstraZeneca's Farxiga for first-line treatment. Later, AZ presented data showing Farxiga's kidney benefits in patients with and without heart failure.